[1]夏洋,周吉林,黄永健,等.康柏西普联合激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿患者远期视力恢复的影响因素研究[J].眼科新进展,2021,41(2):174-177.[doi:10.13389/j.cnki.rao.2021.0037]
　XIA Yang,ZHOU Jilin,HUANG Yongjian,et al.Prognostic factors for visual outcome after injection of Conbercept combined with laser photocoagulation for macular edema due to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2021,41(2):174-177.[doi:10.13389/j.cnki.rao.2021.0037]
点击复制

康柏西普联合激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿患者远期视力恢复的影响因素研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年2期
页码:
174-177
栏目:
应用研究
出版日期:
2021-02-05

文章信息/Info

Title:
Prognostic factors for visual outcome after injection of Conbercept combined with laser photocoagulation for macular edema due to branch retinal vein occlusion
作者:
夏洋; 周吉林; 黄永健; 邹茜; 陶黎明
213000　江苏省常州市，常州市第三人民医院眼科中心（夏洋，周吉林，黄永健，邹茜）；230000　安徽省合肥市，安徽医科大学第二附属医院眼科（陶黎明）
Author(s):
XIA Yang1; ZHOU Jilin1; HUANG Yongjian1; ZOU Xi1; TAO Liming2
1.Department of Ophthalmology,Changzhou Third People’s Hospital,Changzhou 213000,Jiangsu Province,China
2.Department of Ophthalmology,the Second Hospital of Anhui Medical University,Hefei 230000,Anhui Province，China
关键词:
视网膜静脉阻塞; 抗血管内皮生长因子; 黄斑水肿; 光学相干断层扫描血管成像
Keywords:
retinal branch vein occlusion; anti-VEGF;  macular edema; optical coherence tomography angiography
分类号:
R774
DOI:
10.13389/j.cnki.rao.2021.0037
文献标志码:
A
摘要:
目的　分析并评估影响康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)远期视力恢复的因素。方法　回顾性病例分析。将2019年1月至2020年1月在我院眼科查确诊的缺血型BRVO继发ME（BRVO-ME）患者30例30眼纳入研究。所有纳入研究患者均进行裂隙灯检查、最佳矫正视力(BCVA)、光学相干断层扫描(OCT)和光学相干断层扫描血管成像（OCTA）检查，同时测量治疗前后视网膜浅层毛细血管网(SCP)血流密度、黄斑中心凹无血管区域(FAZ）面积和周长，并测量黄斑中心凹厚度（CMT)。定义随访6个月之后的BCVA为远期视力，分析远期视力与基线视力、CMT和OCTA检查参数的相关性。结果　与治疗前相比，治疗6个月后患眼BCVA明显提高，CMT下降显著，差异均有统计学意义（t=11.917、11.334，均为P=0.000）；SCP血流密度有所降低，但差异无统计学意义（t=1.726，P>0.05）；FAZ面积和周长较治疗前均明显增加，差异均有统计学意义（t=-2.554、-6.394，均为P<0.05）。BRVO-ME眼患者注药次数为（2.40±0.89）次。Pearson相关性分析结果显示，远期BCVA与治疗前BCVA、治疗后1个月BCVA降低值以及治疗后1个月CMT下降值均呈正相关（均为P<0.05），而与治疗后1个月SCP血流密度下降值呈负相关（P<0.05），与年龄、治疗前SCP血流密度、治疗前CMT均无相关性（均为P>0.05）。结论　治疗前BCVA、黄斑血流灌注情况、首次治疗后CMT下降程度可作为评估BRVO-ME患者远期视力恢复的影响因素。
Abstract:
Objective　To analyze and evaluate the predictive factors that influence the long-term vision recovery after the treatment of branch retinal vein occlusion (BRVO) secondary to macular edema (ME) with anti-VEGF combined with retinal laser photocoagulation.Methods　Retrospective case analysis. Patients with ischemic BRVO secondary ME (BRVO-ME) diagnosed in the ophthalmology department of our hospital from January 2019 to January 2020 were included in the study, with 30 patients and 30 eyes. All patients included in the study underwent slit lamp examination, best corrected visual acuity (BCVA), optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) examinations, while superficial apillary plexus (SCP) blood flow density, foveal avascular area (FAZ) area and perimeter (PERIM) and manual measurement of central macular thickness (CMT) were measured before and after treatment. The logMAR BCVA after 6 months of follow-up was defined as long-term visual acuity. The correlation between long-term vision and baseline vision, CMT and OCTA parameters were analyzed.Results　Compared with preoperative data, after 6 months of treatment, the BCVA of the affected eye was significantly increased, and the CMT declined obviously, and the differences were statistically significant (t=11.917, 11.334, both P=0.000); SCP blood flow density decreased, but there was no statistical difference (t=1.726, P>0.05); the area of FAZ and PERIM increased significantly compared with before treatment, and the difference was statistically significant (t=-2.554, -6.394, both P<0.05). The average number of injections for BRVO-ME eyes was (2.40±0.89) times. Pearson correlation analysis results showed that long-term logMAR BCVA was positively correlated with logMAR BCVA before treatment, the decrease in logMAR BCVA one month after treatment, and the decrease in CMT one month after treatment (all P＜0.05) and was negatively correlated with blood flow density decrease (P<0.05), and there was no correlation with age, SCP blood flow density before treatment, and CMT before treatment (all P>0.05). Conclusion　The best corrected visual acuity before treatment, macular blood perfusion, and the degree of CMT decline after the first treatment can be used as predictors of long-term vision recovery of patients with BRVO-ME.

参考文献/References:

［1］　CHATZIRALLI I P,JAULIM A,PEPONIS V G,MITROPOULOS P G,MOSCHOS M M.Branch retinal vein occlusion:treatment modalities:an update of the literature［J］.Semin Ophthalmol,2014,29(2):85-107.
［2］　SCHMIDT-ERFURTH U,GARCIA-ARUMI J,GERENDAS B S,MIDENA E,SIVAPRASAD S,TADAYONI R,et al.Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)［J］.Ophthalmologica,2019,242(3):123-162.
［3］　LUPIDI M,COSCAS F,CAGINI C,FIORE T,SPACCINI E,FRUTTINI D,et al.Automated quantitative analysis of retinal microvasculature in normal eyes on optical coherence tomography angiography［J］.Am J Ophthalmol,2016,169（1）:9-23.
［4］　KADOMOTO S,MURAOKA Y,OOTO S,MIWA Y,IIDA Y,SUZUMA K,et al.Evaluation of macular ischemia in eyes with branch retinal vein occlusion:an optical coherence tomography angiography study［J］.Retina,2018,38(2):272-282.
［5］　NOMA H,MINAMOTO A,FUNATSU H,TSUKAMOTO H,NAKANO K,YAMASHITA H,et al.Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion［J］.Graefes Arch Clin Exp Ophthalmol,2006,244(3):309-315.
［6］　WANG Q,LI T,WU Z,WU Q,KE X,LUO D,et al.Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo［J］.PLoS One,2013,8(8):e70544.
［7］　SHIMURA M,YASUDA K.Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease［J］.Br J Ophthalmol,2010,94(3):381-383.
［8］　FUKAMI M,IWASE T,YAMAMOTO K,KANEKO H,YASUDA S,TERASAKI H.Changes in retinal microcirculation after intravitreal ranibizumab injection in eyes with macular edema secondary to branch retinal vein occlusion［J］.Invest Ophthalmol Vis Sci,2017,58(2):1246-1255.
［9］　WAKABAYASHI T,SATO T,HARA-UENO C,FUKUSHIMA Y,SAYANAGI K,SHIRAKI N,et al.Retinal microvasculature and visual acuity in eyes with branch retinal vein occlusion:imaging analysis by optical coherence tomography angiography［J］.Invest Ophthalmol Vis Sci,2017,58(4):2087-2094.
［10］　丁小燕，李加青，于珊珊，吴斌斌，曾婧，刘冉，等.贝伐单抗治疗视网膜中央静脉阻塞黄斑水肿后视力恢复的预测因素分析［J］.中山大学学报:医学科学版,2012,33(1):79-84.
DING X Y，LI J Q，YU S S，WU B B，ZENG J，LIU R，et al.Analysis of predictive factors of vision recovery after bevacizumab treatment of central retinal vein occlusion macular edema［J］.J Sun Yat-sen Univ:Med Sci Edit,2012,33(1):79-84.
［11］　DENG Y,CAI X,ZHANG S,SU L,CHEN H,LIN Y,et al.Quantitative analysis of retinal microvascular changes after conbercept therapy in branch retinal vein occlusion using optical coherence tomography angiography［J］.Ophthalmologica,2019,242(2):69-80.
［12］　SPAIDE R F.Retinal vascular cystoid macular edema:review and new theory［J］.Retina,2016,36(10):1823-1842.
［13］　刘广峰，洪婷婷，苗森，孟忻，王华，贾羽颂，等.玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究［J］.眼科新进展,2017,37(7):658-661.
LIU G F，HONG T T，MIAO S，MENG Y，WANG H，JIA Y S，et al.A clinical control study of intravitreal injection of Conbercept and macular photocoagulation in the treatment of non-ischemic macular edema secondary to branch retinal vein occlusion［J］.Rec Adv Ophthalmol,2017,37(7):658-661.
［14］　HAYREH S S,ZIMMERMAN M B,PODHAJSKY P.Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics［J］.Am J Ophthalmol,1994,117(4):429-441.
［15］　CAMPOCHIARO P A,BHISITKUL R B,SHAPIRO H,RUBIO R G.Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion［J］.Ophthalmology,2013,120(4):795-802.
［16］　PACELLA F,BONGIOVANNI G,MALVASI M,BATTAGLIOLA E T,PISTONE A,SCALINCI S,et al.Impact of cardiovascular risk factors on incidence and severity of retinal vein occlusion［J］.Clin Ter,2020,171(6):e534-e538.

相似文献/References:

[1]王刚.曲安奈德联合氪激光治疗视网膜静脉阻塞的临床疗效观察[J].眼科新进展,2013,33(7):000.
[2]马宇 刘意 郭娟 周利晓.金纳多联合血栓通对视网膜静脉阻塞患者同型半胱氨酸水平的影响[J].眼科新进展,2013,33(9):000.
[3]袁子茗 王帅 宋蓓雯 胡健艳 吴强.维速达尔光动力疗法诱导兔视网膜静脉阻塞的实验研究[J].眼科新进展,2012,32(9):000.
[4]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[5]李娟娟 李燕.先天性及获得性视盘血管袢的临床观察[J].眼科新进展,2013,33(11):000.
[6]刘李平 宋徽 肖云 曹小鹏 白润 陈珍.玻璃体注射雷珠单抗治疗缺血型视网膜中央静脉阻塞的临床观察[J].眼科新进展,2013,33(11):000.
[7]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[8]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[9]刘晶晶,刘子扬,彭清.渗出型年龄相关性黄斑变性的抗血管内皮生长因子治疗进展[J].眼科新进展,2015,35(1):084.[doi:10.13389/j.cnki.rao.2015.0024]
　LIU Jing-Jing,LIU Zi-Yang,PENG Qing.Recent advances in anti-vascular endothelial growth factor for exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2015,35(2):084.[doi:10.13389/j.cnki.rao.2015.0024]
[10]周洁,王宏彬,王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究[J].眼科新进展,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
　ZHOU Jie,WANG Hong-Bin,WANG Wen-Ting.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(2):070.[doi:10.13389/j.cnki.rao.2016.0020]
[11]夏松,陈有信.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].眼科新进展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
　XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(2):1093.[doi:10.13389/j.cnki.rao.2016.0292]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2021-02-05